WHO ICTRP trial
Effects of the anti-inflammatory drug "ROFLUMILAST" on markers of early…
EUCTR2011-004152-19-AT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-004152-19-AT |
|---|---|
| Public title | Effects of the anti-inflammatory drug "ROFLUMILAST" on markers of early atherosclerosis in chronoc bostructive pulmonary disease |
| Scientific title | Effects of ROFLUMILAST on markers of subclinical atherosclerosis In stable COPD; the ELASTIC-trial - the ELASITC-trial |
| Primary sponsor | Ludwig Boltzmann institute for COPD and Respiratory Epidemiology |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Austria |
| Conditions | chronic obstructive pulmonary disease MedDRA version: 14.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract… |
| Interventions | Trade Name: DAXAS Pharmaceutical Form: Coated tablet INN or Proposed INN: roflumilast CAS Number: 162401-32-3 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo… |
| Registration date | Feb 17, 2012 |
| Target size | 80 |
| Secondary IDs | ELASTIC2011 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: